High-dose continuous lenalidomide group	Sequential azacitidine and lenalidomide group and azacitidine only group	Risk of death in the first four months	1269	1421	Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar.
High-dose continuous lenalidomide group	Sequential azacitidine and lenalidomide group and azacitidine only group	Risk of death after 4 months	1269	1421	Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar.
High-dose continuous lenalidomide group	Sequential azacitidine and lenalidomide group and azacitidine only group	Risk of death in the first four months	10684	10947	Subjects in the high-dose continuous lenalidomide cohort had a higher hazard of death than subjects in the azacitidine cohort [HR 5.73 (1.91, 17.20); P=0.002] or subjects in the sequential azacitidine and lenalidomide cohort [HR 2.19 (95%CI: 0.94, 5.13); P=0.071]
